Allogeneic peripheral blood hematopoietic stem cell transplantation for patients with hematologic malignancies

Abstract

To investigate the therapeutic effects and associated complications of allogeneic peripheral blood stem cell transplantation (allo-PBSCT). 10 patients with various malignant hematopoietic diseases received allo PBSCT. The preparative regimens were based on BUCY2 or modified BUCY2. The acute graft versus host disease (aGVIII) was prevented by cyclosporin A and shortterm MTX regimen in all patients. Two patients from donors with one fully mismatched HLA on DRB1 locus and 4 from unrelated donor also administered Zenapox (CD25 MAb) at dosage of 1 mg/kg every day on the day before transplantation and day 1 after transplantation. These 6 patients were also treated with mycophenolate mofetil (MMF). Transfusion of the donor cells: The median of the transfused nucleated cells was 5.38<10⁸/kg and that of the CD34′ cells was 7.8×10⁶/kg respectively. All the patients gained hematopoietic reconstruction except one who died of infection before engraftment. Seven patients got II′ IV^o aGVHD, and the incidence was 17.5%. Fourteen patients got cGVHD and the incidence was 53.8% in the patients who survived over 6 months. Twenty-eight patients had fever or other characteristics of infection. The median follow-up time was 13.8 months. The incidence of transplantation related mortality (TRM) was 17.5% and 2 patients relapsed (5.0_). It was concluded that allo PBSCT can reconstruct hematopoiesis quickly and is a favorable therapeutic method for leukemia.

Keywords

leukemia / peripheral blood stem cell transplantation, allogeneic / graft-vesus-host disease

References

[1] ChamplinR E, SchmitzN. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogenetic transplantation. Blood, 2000, 95: 3702-3709

[2] PowlesR, MehtaJ, KulkarniS, et al.. Allogenetic blood and bone marrow stem-cell transplantation in haematological malignant disease: a randomized trial. Lancet, 2000, 335: 1231-1237

[3] GratwohlA, BrandR, ApperleyJ, et al.. Graft-versushost disease and outcome in HLA-identical sibing transplantations for chronic myeloid leukemia. Blood, 2002, 100: 3877-3886

[4] LeeS J, KleinJ P, BarrettA J, et al.. Severity of chronic graft-versus host disease: association with treatment-related mortality and relapse. Blood, 2002, 100: 406-414

[5] MohtyM, KuentzM, MichalletM, et al.. Chronic graftversus-host disease after allogenetic blood stem cell transplantation: long-term results of a randomized study. Blood, 2002, 100: 3128-3134

[6] LiY, HuangS L, FangJ P, et al.. Clinical analysis of 29 cases with early infection after hematopoietic stem cell transplantation. Chin J Pediatr (Chinese), 2003, 41: 520-524

[7] EvansP C, GrayJ J, WrerhittT G, et al.. Comparison of three PCR techniques for detecting cytomegalovirus DNA in serum, detection of early antigen fluorescent foci and culture for the diagnosis of CMV infection. J MED Microbio, 1999, 46: 1029-1035